

April 22, 2022  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## **Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors**

Symbio Pharmaceuticals Limited (“the Company”) announces that the following details have finalized today regarding the stock acquisition rights to be issued to the Company's Directors as stock options (the 56th Series Symbio Stock Option) based on the resolution of the Board of Directors' meeting on March 29, 2022.

1. Number of stock acquisition rights  
3,200 (in total for 5 directors)
  
2. Class and number of stocks to be issued upon exercise of the stock acquisition rights  
The Company's common stock : 80,000 shares
  
3. Amount to be paid for stock options and calculation method
  - (1) Amount to be paid per one stock option : 17,200 yen
  - (2) Amount to be paid per one share : 688 yenThe person who receives the allotment of stock acquisition rights shall set off his/her claims for compensation against the Company in lieu of payment of monies for the stock acquisition rights allotted.

(Note)

For further details of the stock acquisition rights, please refer to the Company's press release dated March 29, 2022, “Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors.”

### **[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125